DUPUYTREN LITERATURE: MORTALITY AND MALIGNANCY

These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Dupuytren disease is associated with a higher risk of premature death. Some of this risk is due to increased cancer risk. Cancer relates to Dupuytren disease in four ways. The first, the most common association is higher cancer rates in those with Dupuytren disease (although not in their families):

• Gudmundsson KG, Arngrímsson R, Sigfússon N, Jónsson T. Increased total mortality and cancer mortality in men with Dupuytren’s disease: a 15-year follow-up study. J Clin Epidemiol 2002;55:5–10. (PDF)
• Kuo RYL, Ng M, Prieto-Alhambra D, Furniss D. Dupuytren’s disease predicts increased all-cause and cancer-specific mortality: analysis of a large cohort from the UK Clinical Practice Research Datalink. Plast Reconstr Surg. December 2019. doi:10.1097/PRS.0000000000006551 (PDF)
• Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P. Direct and indirect costs associated with Dupuytren’s contracture. J Med Econ 2012; 15:71–664. (PDF)
• Mikkelsen OA, Hoyeraal HM, Sandvik L. Increased Mortality in Dupuytren’s Disease. J Hand Surg Br 1999;24:1–5. (PDF)
• Wilbrand S, Ekbom A, Gerdin B. A cohort study linked increased mortality in patients treated surgically for Dupuytren’s contracture. J Clin Epidemiol 2005; 58:68–74. (PDF)
• Wilbrand S, Ekbom A, Gerdin B. Cancer incidence in patients treated surgically for Dupuytren’s contracture. J Hand Surg Br 2000;25:283–7. (PDF)
• Wilbrand S, Ekbom A, Gerdin B. Dupuytren’s Contracture and Sarcoma. J Hand Surg 2002 27B(1),50–52. (PDF)
• Zyluk A, Paszkowska-Szczur K, Gupta S, Scott RJ, Lubinski J, Debniak T. Dupuytren’s disease and the risk of malignant neoplasms. Hered Cancer Clin Pract 2014;12:6. (PDF)

Second, a less common cancer association is palmar fasciitis arising in the context of known cancer. Palmar fasciitis is similar to Dupuytren disease but rare, and it probably should not be called Dupuytren disease:

• De Carli P, Boretto J, Bourgeois W, Gallucci G. Hand involvement in paraneoplastic syndrome: a case report. J Hand Surg Am 2005;30:1087–90. (PDF)
• Denschlag D, Riener E, Vaith P, Tempfer C, Keck C. Palmar fasciitis and polyarthritis as a paraneoplastic syndrome associated with tubal carcinoma: a case report. Ann Rheum Dis 2004;63:1177–8. (PDF)
• Haroon M, Phelan M. A paraneoplastic case of palmar fasciitis and polyarthritis syndrome. Nat Clin Pr Rheumatol 2008;4:27–274. (PDF)
• Martorell E a, Murray PM, Peterson JJ, Menke DM, Calamia KT. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am 2004;29:654–60. (PDF)
• Qureshi AA, Saavedra A. Palmar fasciitis and polyarthritis syndrome in patients with ovarian cancer-a case report and review of the literature. Hand (N Y) 2011; 6 :23–220. (PDF)
• Veitch D, Tsai T, Joshua F. Palmar fasciitis and polyarthritis syndrome in pancreatic carcinoma. J Clin Rheumatol 2013; 19:25–203. (PDF)
• Willemse PH, Mulder NH, van de Tempel HJ, Aalders JG, Sleijfer DT. Palmar fasciitis and arthritis in a patient with an extraovarian adenocarcinoma of the coelomic epithelium. Ann Rheum Dis 1991;50:53–4. (PDF)

The third cancer association is Dupuytren disease (or something which looks very much like it) triggered by treatment with matrix metalloproteinase inhibitors and other cancer chemotherapy agents:

• Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren’s disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998;80:907–8. (PDF)
• Chan Sze Wai, Vorobiof Daniel Alberto. (2015). “Dupuytren’s Contractures Associated with the BRAF Inhibitor Vemurafenib: A Case Report.” Journal of Medical Case Reports 9 (1). Journal of Medical Case Reports 158. (PDF)
• Sibaud Vincent, Chevreau Christine. (2014). “Abrupt Development of Dupuytren’s Contractures with the BRAF Inhibitor Vemurafenib.” Joint, Bone, Spine: Revue Du Rhumatisme 33 (0): 9–11. (PDF)
• Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109. (PDF)
• Vandersleyen V, Grosber M, Wilgenhof S, De Kock J, Neyns B, Gutermuth J. Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients. J Eur Acad Dermatology Venereol. 2015. (PDF)
• Zabraniecki L, Doub A, Mularczyk M et al. (1998) Frozen shoulder: a new delayed complication of protease inhibitor therapy? Revue Du Rhumatisme (English Ed.) 65, 72–74. (PDF)

Finally, malignancy may very rarely involve the hand and have a similar appearance to Dupuytren disease – which it is not:

• Erdmann MW, Quaba AA, Sommerlad BC. Epithelioid sarcoma masquerading as Dupuytren’s disease. Br J Plast Surg 1995;48:39–42. (PDF)
• Power R a, Manek S, McCullough CJ. Spindle-cell sarcoma of the hand may present as a benign recurrent nodule. vol. 74. 1992. (PDF)
• Ragois P, Didailler P, Rizzi P. Skin metastasis of lung carcinoma like Dupuytren’s disease. Chir Main 2012;31:259–61. (PDF)